# Phase III Study of AK112 for NSCLC Patients

Source: https://onco.cc/trials/nct06396065/  
OnCo record `nct06396065` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, active and no longer recruiting.

## Summary

Phase III Study of AK112 for NSCLC Patients is a phase 3 interventional study registered as NCT06396065 by Summit Therapeutics, with 420 participants enrolled, started 2023-05-04 and due to reach its primary completion in 2025-04-12. Interventions recorded: AK112 Injection, Placebo Injection. Conditions listed: Non-Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06396065
- Phase: 3
- Setting: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
- Sponsor: Summit Therapeutics
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT06396065: https://clinicaltrials.gov/study/NCT06396065

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06396065.json